Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Next Previous
X
Search
Trial Profile

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Fluocinolone acetonide; Hydrocortisone; Triamcinolone
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms CHRONOS; LIBERTY AD CHRONOS
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 26 Feb 2024 Results studying the impact of dupilumab treatment on total IgE levels in association with the probability of having flares in patients with moderate-to-severe AD, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 27 Feb 2023 Results of pooled analysis (from 6 phase 3 studies (NCT03346434, NCT03345914, NCT03054428, NCT02260986, NCT02277743 and NCT02277769) assessing IgE levels in patients aged 6 months and older with moderate-to-severe AD presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 20 Feb 2023 Post-hoc pooled data (N=2444) analysis evaluating efficacy and safety of dupilumab in patients aged greater than or equal to 60 years with moderate-to-severe atopic dermatitis from NCT02277743, NCT02277769, NCT02755649, NCT02260986, published in the American Journal of Clinical Dermatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top